BioDelivery Sciences and Meda expand distribution deal
This article was originally published in Scrip
BioDelivery Sciences(BDSI) and Medahave expanded their commercial partnership. The Swiss company now has the global rights to distribute BioDelivery's lead product Onsolis (fentanyl buccal soluble film) in all countries except Taiwan and South Korea in return for $3 million. BDSI had previously licensed to Meda the rights to distribute Onsolis, a treatment for breakthrough pain in opioid-tolerant patients with cancer, in the US, Canada, Mexico and Europe. Meda will pay BDSI a $3 million advance on the anticipated $30 million milestone Meda owes for Onsolis. BDSI expects Onsolis to receive approval from the US FDA during the second quarter.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.